Printer Friendly

BARR REINTRODUCES TWO ADDITIONAL PRODUCTS

 POMONA, N.Y., June 14 /PRNewswire/ -- Barr Laboratories, Inc. (AMEX: BRL) today announced the reintroduction of all package sizes of Dipyridamole 25 mg tablets, a generic equivalent to Boehringer Ingelheim's Persantine(R) and Isoniazid Tablets, USP 300mg tablets. Both products will be shipped immediately.
 The reintroduction of Dipyridamole 25mg tablets and Isoniazid USP 300mg marks the second and third products respectively to be reinstated following FDA review of Barr validation studies.
 Isoniazid is an important drug used in the treatment and prevention of tuberculosis in the United States, and more recently, as an adjunct in AIDS drug therapy.
 The incidence of AIDS and tuberculosis cases have climbed dramatically in recent years to nearly epidemic proportions in some large inner city environments. This makes the reintroduction of generic Isoniazid 300mg a vitally important public health issue.
 "While Dipyridamole and Isoniazid are both very important products to Barr and American consumers, we are particularly pleased to announce the reintroduction of Isoniazid," said Bruce Downey, president, Barr Laboratories. "With the staggering increase of AIDS and tuberculosis cases in the United States over the past decade, it is comforting for the American consumer and government health agencies to know that low cost generic treatment is available."
 The reintroduction of Dipyridamole 25mg completes Barr's line of Dipyridamole products that includes a 50mg and 75mg tablets as well. All are available in bottles of 100, 500 and 1,000.
 The reintroduction of Isoniazid, USP 300mg completes Barr's line of Isoniazid products that also includes a 100mg strength. The 300mg tablet is available in bottles of 30, 100 and 1,000 while the 100mg strength is available in bottles of 100 and 1,000.
 The two products account for approximately $1.5 million in sales on an annualized basis.
 The Federal District Court in Newark, N.J., required completion of additional validation prior to reintroduction of these products. Barr and the FDA agree that the additional studies completed for Dipyridamole 25mg tablets and Isoniazid Tablets, USP 300mg satisfy the FDA's requirements. The company is preparing additional validation studies on its remaining suspended products.
 "We continue to work with FDA and expect reintroduction of other products over the next several weeks," said Downey.
 Barr Laboratories is a manufacturer of a broad range of multi-source pharmaceutical products with manufacturing facilities located in Northvale, N.J., and Pomona, N.Y.
 -0- 6/14/93
 /CONTACT: Harold Cohen of Barr Laboratories, 914-362-2823/
 (BRL)


CO: Barr Laboratories, Inc. ST: New York IN: MTC SU: PDT

TS-PS -- NY052 -- 1600 06/14/93 11:28 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 14, 1993
Words:422
Previous Article:ANGEION REPORTS THIRD QUARTER FIGURES
Next Article:PECO NAMES JUNE DOUGLAS FIRST WOMAN MANAGER OF PECO GENERATING STATION
Topics:


Related Articles
BARR REINTRODUCES E.S.P.
BARR REINTRODUCES THREE ANTIBIOTICS
BARR REINTRODUCES ANTI-ANXIETY DRUG
BARR REINTRODUCES ANTI-ANXIETY DRUG
BARR REINTRODUCES ANTI-ANXIETY DRUG
BARR REINTRODUCES ANTI-ANXIETY DRUG
BARR LABORATORIES, FDA SETTLE 1992 COURT CASE; COURT'S ORDER ESTABLISHES PROCESS FOR COMPANY TO REINTRODUCE FORMER PRODUCTS
Barr Reintroduces Generic Demerol 100 mg Tablets; First Product in Company's Revitalized Pain Management Category
Barr Launches Tamoxifen Citrate 20mg Tablets
Barr's First Proprietary Product Receives FDA Approval; Contraceptive Product Co-Developed with Gynetics, Inc.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters